This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
BM
MetabolicVerified
Bitter Melon Metabolic
Momordica charantia
Blood sugar management in tropical traditional medicine worldwide
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Momordica charantia is a tropical vine used as a vegetable and medicinal herb, primarily recognized for its glucose-lowering effects in diabetes management [PMID:32951763, PMID:35408574].
Background
Momordica charantia, also known as bitter gourd, karela, or balsam pear, is a member of the Cucurbitaceae family cultivated in tropical and subtropical regions [PMID:31487939, PMID:35656300].
Traditional uses
It has been used in the traditional medicine of China, India, and Sri Lanka to treat various diseases, serving as a stomachic, laxative, anthelmintic, and for the treatment of diabetes and its complications [PMID:31487939, PMID:35656300].
Active compounds
Bioactive components include charantin, polypeptide-p (p-insulin), vicine, triterpenoids (such as momordicine I), saponins, flavonoids, phenolic acids, alkaloids, and polysaccharides [PMID:16910221, PMID:30790347, PMID:39408847, PMID:28503051].
Mechanism of action
Hypoglycemic effects are achieved by increasing pancreatic insulin secretion, decreasing insulin resistance, increasing peripheral and skeletal muscle glucose utilization, and inhibiting intestinal glucose absorption [PMID:30790347, PMID:28474032]. Other mechanisms include antioxidant activity via scavenging reactive oxygen species (ROS) and modulating inflammatory pathways [PMID:40170075, PMID:39408847].
Clinical evidence
Evidence BType 2 Diabetes Mellitus
Bitter melon extract significantly decreased average fasting glucose levels over 12 weeks, although HbA1c levels remained unchanged [PMID:32951763].
Evidence BDiabetes (Non-insulin-dependent)
Water-soluble extract of fruits significantly reduced blood glucose concentrations during a 50 g oral glucose tolerance test [PMID:6786635].
Evidence BPrediabetes
Supplementation for twelve weeks improves biomarkers of glucose homeostasis [PMID:40199408].
Safety & adverse effects
Reported adverse effects include headaches, a favism-like syndrome, increases in alkaline phosphatase and gamma-glutamyltransferase levels in animals, and severe reactions such as convulsions and hypoglycemic coma in children [PMID:12625217].
Drug interactions
Bitter melon may have additive effects when taken concurrently with other glucose-lowering agents [PMID:12625217].
Evidence summary
There is moderate clinical evidence (RCTs) supporting the hypoglycemic effects of M. charantia in diabetic and prediabetic populations, while extensive preclinical data (reviews/animal studies) suggest broader anti-inflammatory and antioxidant properties.
PubMed sources
1.PMID: 32951763 (2020) — Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus. · Complementary therapies in medicine
2.PMID: 40170075 (2025) — Oral administration of Momordica charantia-derived extracellular vesicles alleviates ulcerative colitis through comprehensive renovation of the intestinal microenvironment. · Journal of nanobiotechnology
3.PMID: 31487939 (2019) — The Role of Momordica charantia in Resisting Obesity. · International journal of environmental research and public health
4.PMID: 35408574 (2022) — Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents. · Molecules (Basel, Switzerland)
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
— Momordica charantia L.-Diabetes-Related Bioactivities, Quality Control, and Safety Considerations.
· Frontiers in pharmacology
6.PMID: 12625217 (2003) — Bitter melon (Momordica charantia): a review of efficacy and safety. · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
7.PMID: 40199408 (2025) — Bitter gourd (Momordica charantia L.) supplementation for twelve weeks improves biomarkers of glucose homeostasis in a prediabetic population. · Journal of ethnopharmacology
8.PMID: 16910221 (2006) — Bitter gourd (Momordica Charantia): A dietary approach to hyperglycemia. · Nutrition reviews
9.PMID: 30790347 (2019) — Possible molecular mechanisms of glucose-lowering activities of Momordica charantia (karela) in diabetes. · Journal of cellular biochemistry
10.PMID: 28503051 (2017) — An Update Review on the Anthelmintic Activity of Bitter Gourd, Momordica charantia. · Pharmacognosy reviews
11.PMID: 28474032 (2017) — Momordica charantia: a popular health-promoting vegetable with multifunctionality. · Food & function
12.PMID: 6786635 (1981) — Improvement in glucose tolerance due to Momordica charantia (karela). · British medical journal (Clinical research ed.)
13.PMID: 39408847 (2024) — Therapeutic Potential of Momordicine I from Momordica charantia: Cardiovascular Benefits and Mechanisms. · International journal of molecular sciences